Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
about
Uncommon cause of recurrent infectionsCongenital neutropenia: diagnosis, molecular bases and patient management.Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.Cyclic neutropenia and severe congenital neutropenia in patients with a shared ELANE mutation and paternal haplotype: evidence for phenotype determination by modifying genes.Neutrophil disorders and their management.Severe congenital neutropenia in a multigenerational family with a novel neutrophil elastase (ELANE) mutation.The investigation and management of chronic neutropenia in children.Transplantation for congenital bone marrow failure syndromes.A truncation mutant of Csf3r cooperates with PML-RARα to induce acute myeloid leukemia in mice.The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapyDistinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cellsCanadian supportive care recommendations for the management of neutropenia in patients with cancer.ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiologyWnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia patient-derived pluripotent stem cells.A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantationBoth systemic and local application of granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy.G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia.Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS.Cataract associated with high-dose hematopoietic colony stimulating factor, case report and literature review.Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.Genetic correction of HAX1 in induced pluripotent stem cells from a patient with severe congenital neutropenia improves defective granulopoiesis.Case 2: Where have all the white cells gone?The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome.
P2860
Q24596575-AC4D8A5A-3EBB-41D9-BF05-71A4BD67C9BBQ33395402-E5B66155-29D1-451D-AED5-1C2FAA7976A6Q33428604-6CF5B9F5-E26C-40A9-85A5-0D707C1EB183Q33780538-C67F621B-EACF-4776-815C-33DCF5BF0DAEQ34005674-3C0AFFAD-778A-4BF6-AD1A-3E693A30C34AQ34033152-050924F1-DD79-42B4-BF1D-000A1F3346C6Q34197117-FB645225-29DD-4F3F-987F-CBBB9D912503Q34477288-76C59D4A-A0F1-4BB5-966F-897408F69842Q34567825-A55D0008-59A8-4823-852A-77973C007F2FQ35428973-89AEF8B1-DD93-4089-80F4-05B8D63BB4FCQ35564931-CA5DD13F-1AB8-4568-BBEB-6DA8CFEE0468Q35849723-5F0EFA63-07A9-4781-AAE2-75401EE959BCQ35989473-BB8158B2-1BEA-4377-81E3-B699B5490334Q36040510-C4CC9D84-3A3F-4593-8F43-6D4FD29F7820Q36485208-0E1FF2BD-75E3-4948-BF38-BA0195FCDEE8Q36573828-8195213C-4E2A-4E8B-A071-71D2E336B6C2Q36637446-C8D93FD6-00FD-47B0-BE96-924FD4C64479Q36941032-5048378F-048A-469E-A1C1-DD1DFA1939BAQ37214453-67C01D7D-27A0-49A8-9BF4-53050C43AFAEQ37369951-AD9EEE5B-E256-4F89-A9E5-8D3171FD35FEQ37952706-92A20072-45AD-4049-9F70-C0D52DFD1FD9Q38130227-8BD19E06-C694-4BB0-95D1-25A28915A882Q38993081-22C81586-AB4B-469B-88B7-E08EF35080DBQ39105427-5A71A798-236C-4C96-9F22-FABD4A587408Q41458396-1B7A09A4-DE5F-4E94-9C15-6A80BE94D17EQ47125123-66557BE1-74C2-4993-9257-FDFC02CAA0E1
P2860
Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Myelodysplasia syndrome and ac ...... penia receiving G-CSF therapy.
@en
Myelodysplasia syndrome and ac ...... penia receiving G-CSF therapy.
@nl
type
label
Myelodysplasia syndrome and ac ...... penia receiving G-CSF therapy.
@en
Myelodysplasia syndrome and ac ...... penia receiving G-CSF therapy.
@nl
prefLabel
Myelodysplasia syndrome and ac ...... penia receiving G-CSF therapy.
@en
Myelodysplasia syndrome and ac ...... penia receiving G-CSF therapy.
@nl
P2093
P1433
P1476
Myelodysplasia syndrome and ac ...... openia receiving G-CSF therapy
@en
P2093
Bolyard AA
Bonilla MA
Freedman MH
Kannourakis G
P304
P407
P577
2000-07-01T00:00:00Z